Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 46 Carcinoma, Non-Small-Cell Lung 42 Carcinoma, Renal Cell 29 Neoplasms 24 Neoplasm Metastasis 20 Colorectal Neoplasms 17 Carcinoma, Hepatocellular 15 Stomach Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 14 Ovarian Neoplasms 14 Triple Negative Breast Neoplasms 13 Lung Neoplasms 11 Pancreatic Neoplasms 9 Head and Neck Neoplasms 8 Carcinoma, Transitional Cell 8 Small Cell Lung Carcinoma 7 Recurrence 7 Hodgkin Disease 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Prostatic Neoplasms 6 Endometrial Neoplasms 6 Carcinoma, Merkel Cell 6 Breast Neoplasms 6 Uterine Cervical Neoplasms 5 Glioblastoma 5 Advanced Cancer 5 Uveal Melanoma 4 Solid Tumor 4 Mesothelioma 4

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 durvalumab 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡